Non-small Cell Lung Cancer
Conditions
Keywords
Fractionated stereotactic radiotherapy, Medically inoperable, Image-guided radiotherapy
Brief summary
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects. This study is developing stereotactic radiotherapy as a state-of-the-art treatment for lung cancer patients.
Detailed description
OBJECTIVES: Primary Objectives * To determine the efficacy of hypofractionated, image guided radiotherapy in treating patients with lung tumours, with the primary outcome being local control at one year. * To determine the toxicity of high dose, small field,hypofractionated radiotherapy to the lung, based on the RTOG and CTCAE scales.
Interventions
RADIATIONStereotactic Radiotherapy
Stereotactic Radiotherapy
Sponsors
Cross Cancer Institute
AHS Cancer Control Alberta
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* T1-T3N0 non-small cell lung cancer (maximum dimensions of 5cm, T3 by chestwall involvement only) * Medically inoperable due to co-morbid conditions or patient preference for radiation * adequate pulmonary function to withstand radical treatment (ie. FEV1 greater than 40% of predicted), as assessed by consulting radiation oncologist * age greater than or equal to 18, and Karnofsky performance status greater than of equal to 70
Exclusion criteria
* Presence of mediastinal metastases or distant metastases * Life expectancy less than 1 year due to other co-morbid conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local Control | One Year |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity | One Year |
| Quality of Life | One Year |
Countries
Canada
Outcome results
None listed